

# Revascularisation or medical therapy in elderly patients with acute anginal syndromes

<b>Submission date</b> 13/03/2014	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 13/03/2014	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 13/10/2021	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Acute coronary syndrome (ACS) is a term referring to various heart conditions, including heart attacks. Despite the enormous amount of research around ACS, there is only a very small amount of data on the management of ACS in the elderly, octogenarian population. About 33% of all ACS episodes in the UK occur in patients aged over 75. The incidence of ACS in the octogenarian is projected to increase due to advances in ACS treatment in an aging population. A non-ST segment elevation myocardial infarction (NSTEMI) is a less serious heart attack where the supply of blood to the heart is only partially blocked. Treatment for NSTEMI can be divided into two groups: optimal medical therapy (OMT) or OMT plus revascularisation. OMT consists of the medications heparin, aspirin, clopidogrel, beta blocker and a statin followed by a plan to optimise long-term medical treatment in order to reduce future cardiac events. OMT plus revascularisation refers to OMT together with a coronary angiogram (X-ray of the heart) followed by either stent insertion or coronary artery bypass graft surgery (CABG). As yet, no large studies comparing OMT with OMT plus revascularisation have been undertaken in octogenarian patients. The small amount of data that is available appears to demonstrate a greater benefit from revascularisation, yet it is common for this to be denied to them. Our aim is to recruit over 700 patients aged 80 or over to a study comparing OMT with OMT plus revascularisation.

### Who can participate?

NSTEMI patients aged 80 or over

### What does the study involve?

Participants are randomly allocated to be treated with either OMT or OMT plus revascularisation.

### What are the possible benefits and risks of participating?

Not provided at time of registration

### Where is the study run from?

Brighton and Sussex University Hospitals NHS Trust (UK)

When is the study starting and how long is it expected to run for?  
April 2014 to September 2019

Who is funding the study?  
Medtronic International Trading Sàrl

Who is the main contact?  
Mr Duncan Fatz  
duncan.fatz@bsuh.nhs.uk

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Mr Duncan Fatz

**Contact details**  
Brighton and Sussex University Hospitals NHS Trust  
HIV Research Office  
Sussex House  
Abbey Road  
Brighton  
United Kingdom  
BN2 1ES  
-  
duncan.fatz@bsuh.nhs.uk

## Additional identifiers

**ClinicalTrials.gov (NCT)**  
NCT02086019

**Protocol serial number**  
16226

## Study information

**Scientific Title**  
Revascularisation or medical therapy in elderly patients with acute anginal syndromes

**Acronym**  
RINCAL

**Study objectives**  
The aim is to recruit over 700 patients 80 years or over to a randomised controlled trial comparing revascularisation plus OMT (invasive arm) versus optimal medical therapy (conservative arm).

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

London - Brighton & Sussex Research Ethics Committee, 27/11/2013, ref: 13/LO/1082

**Study design**

Randomised; Interventional; Design type: Not specified

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Topic: Cardiovascular; Subtopic: Cardiovascular (all Subtopics); Disease: Atherothrombosis

**Interventions**

Percutaneous coronary intervention (PCI) or Coronary Artery Bypass Graft (CABG)

**Intervention Type**

Mixed

**Primary outcome(s)**

Composite at 1 year of:

1. Death
2. Non-fatal myocardial infarction

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

01/09/2019

**Eligibility****Key inclusion criteria**

1. Age 80 or over
2. Non STEMI characteristic chest pain accompanied by typical ischaemic ECG changes a troponin rise
3. Suitable for conservative or invasive strategy

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Senior

**Sex**

All

**Total final enrolment**

251

**Key exclusion criteria**

1. Acute STEMI
2. Cardiogenic shock
3. Lack of suitability for whatever clinical reason to be randomised (any condition in the opinion of the Investigator would make it unsafe or unsuitable for the patient to participate in the study)
4. Platelet count  $\leq 50 \times 10^9/\text{mm}^3$
5. Patient life expectancy  $< 1$  year
6. Known allergies to clopidogrel, aspirin, heparin, stainless steel, IV contrast or stent
7. Drug elutant
8. Recent major GI haemorrhage (within 3 months)
9. Any previous cerebral bleeding episode
10. Participation in another investigational drug or device study
11. Patient unable to give consent
12. Clinical decision precluding the use of stents

**Date of first enrolment**

01/04/2014

**Date of final enrolment**

01/09/2018

**Locations**

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

Brighton and Sussex University Hospitals NHS Trust

Brighton

United Kingdom

BN2 1ES

**Sponsor information**

**Organisation**

## Funder(s)

### Funder type

Industry

### Funder Name

Medtronic; Grant Codes: UK- SHQ SBU

### Alternative Name(s)

Medtronic Inc.

### Funding Body Type

Private sector organisation

### Funding Body Subtype

For-profit companies (industry)

### Location

United States of America

## Results and Publications

### Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Dr Adam de Belder (a.debelder@nhs.net).

### IPD sharing plan summary

Available on request

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		17/05/2021	11/10/2021	Yes	No
<a href="#">HRA research summary</a>			28/06/2023	No	No